Log in

Relevant bibliographies by topics / Chemotherapeutic and Targeted Therapies / Journal articles

To see the other types of publications on this topic, follow the link: Chemotherapeutic and Targeted Therapies.

Journal articles on the topic 'Chemotherapeutic and Targeted Therapies'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Chemotherapeutic and Targeted Therapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Khunger, Niti, Shankila Mittal, and SatyaPal Kataria. "Nail changes with chemotherapeutic agents and targeted therapies." Indian Dermatology Online Journal 13, no. 1 (2022): 13. http://dx.doi.org/10.4103/idoj.idoj_801_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Reyes-Habito, Claire Marie, and Ellen K. Roh. "Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer." Journal of the American Academy of Dermatology 71, no. 2 (2014): 203.e1–203.e12. http://dx.doi.org/10.1016/j.jaad.2014.04.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Norden, Andrew D., Jan Drappatz, and Patrick Y. Wen. "Targeted drug therapy for meningiomas." Neurosurgical Focus 23, no. 4 (2007): E12. http://dx.doi.org/10.3171/foc-07/10/e12.

Full text

Abstract:

✓ Although advances in surgery, radiation therapy, and stereotactic radiosurgery have significantly improved the treatment of meningiomas, there remains an important subset of patients whose tumors are refractory to conventional therapy. Treatment with traditional chemotherapeutic agents has provided minimal benefit. In this review, the role of targeted molecular therapies for recurrent or progressive meningiomas is discussed.

APA, Harvard, Vancouver, ISO, and other styles

4

Chung, Clement, and Rosetta Lee. "Neoadjuvant Chemotherapeutic and Targeted Therapies for Early-stage, High-risk Breast Cancer." European Oncology & Haematology 10, no. 01 (2014): 28. http://dx.doi.org/10.17925/eoh.2014.10.1.28.

Full text

Abstract:

Neoadjuvant or preoperative chemotherapy is the preferred treatment for locally advanced, inflammatory and early-stage high-risk breast cancers. Patients with locally advanced breast cancers are candidates for neoadjuvant therapy because their tumours are often not amenable to resection. On the other hand, patients are candidates for neoadjuvant chemotherapy if the breast-conserving surgery is not possible. At present, anthracycline- and taxane-based chemotherapy regimens remain as the cornerstone for neoadjuvant therapy in early breast cancer, but there is a clear need for effective therapies

APA, Harvard, Vancouver, ISO, and other styles

5

Setlai, Botle Precious, Rodney Hull, Meshack Bida, et al. "Immunosuppressive Signaling Pathways as Targeted Cancer Therapies." Biomedicines 10, no. 3 (2022): 682. http://dx.doi.org/10.3390/biomedicines10030682.

Full text

Abstract:

Immune response has been shown to play an important role in defining patient prognosis and response to cancer treatment. Tumor-induced immunosuppression encouraged the recent development of new chemotherapeutic agents that assists in the augmentation of immune responses. Molecular mechanisms that tumors use to evade immunosurveillance are attributed to their ability to alter antigen processing/presentation pathways and the tumor microenvironment. Cancer cells take advantage of normal molecular and immunoregulatory machinery to survive and thrive. Cancer cells constantly adjust their genetic ma

APA, Harvard, Vancouver, ISO, and other styles

6

Lee, Eun Hye, Se Hyun Kwak, Chi Young Kim, Hye Ran Gwon, Eun Young Kim, and Yoon Soo Chang. "New targeted therapies for non-small cell lung cancer." Journal of the Korean Medical Association 66, no. 3 (2023): 180–90. http://dx.doi.org/10.5124/jkma.2023.66.3.180.

Full text

Abstract:

Background: Lung cancer is representative of a high frequency and high mortality disease and ranks at the top in incidence and mortality in Korea, when excluding thyroid cancer. In this manuscript, we focused on current targeted therapies for lung cancer used widely in the medical field.Current Concepts: The majority of patients with lung cancer cannot be treated with surgery only and require chemotherapeutics or radiation therapy. Currently, classical chemotherapeutic agents, targeted agents, and immune checkpoint inhibitors are the most widely used. Recently, the Research and Development of

APA, Harvard, Vancouver, ISO, and other styles

7

Taylor, Wesley F., Maria Yanez, Sara E. Moghadam, et al. "7-epi-Clusianone, a Multi-Targeting Natural Product with Potential Chemotherapeutic, Immune-Modulating, and Anti-Angiogenic Properties." Molecules 24, no. 23 (2019): 4415. http://dx.doi.org/10.3390/molecules24234415.

Full text

Abstract:

Targeted therapies have changed the treatment of cancer, giving new hope to many patients in recent years. The shortcomings of targeted therapies including acquired resistance, limited susceptible patients, high cost, and high toxicities, have led to the necessity of combining these therapies with other targeted or chemotherapeutic treatments. Natural products are uniquely capable of synergizing with targeted and non-targeted anticancer regimens due to their ability to affect multiple cellular pathways simultaneously. Compounds which provide an additive effect to the often combined immune ther

APA, Harvard, Vancouver, ISO, and other styles

8

Nerkar, A. G. "Metastatic melanomas: Treatment overview." Current Trends in Pharmacy and Pharmaceutical Chemistry 3, no. 4 (2021): 50–55. http://dx.doi.org/10.18231/j.ctppc.2021.013.

Full text

Abstract:

Melanomas especially metastatic melanoma chemotherapeutic treatment has been discussed in the review article. The recent advancement in the chemotherapy being Immunotherapy targeted therapy, combination therapy, targeted therapy, combination therapies and biochemotherpies all of which have been discussed in this review article.

APA, Harvard, Vancouver, ISO, and other styles

9

Qian, Xian-ling, Jun Li, Ran Wei, Hui Lin, and Li-xia Xiong. "Internal and External Triggering Mechanism of “Smart” Nanoparticle-Based DDSs in Targeted Tumor Therapy." Current Pharmaceutical Design 24, no. 15 (2018): 1639–51. http://dx.doi.org/10.2174/1381612824666180510094607.

Full text

Abstract:

Background: Anticancer chemotherapeutics have a lot of problems via conventional Drug Delivery Systems (DDSs), including non-specificity, burst release, severe side-effects, and damage to normal cells. Owing to its potential to circumventing these problems, nanotechnology has gained increasing attention in targeted tumor therapy. Chemotherapeutic drugs or genes encapsulated in nanoparticles could be used to target therapies to the tumor site in three ways: “passive”, “active”, and “smart” targeting. Objective: To summarize the mechanisms of various internal and external “smart” stimulating fac

APA, Harvard, Vancouver, ISO, and other styles

10

Starace, Michela, Luca Rapparini, and Stephano Cedirian. "Skin Malignancies Due to Anti-Cancer Therapies." Cancers 16, no. 11 (2024): 1960. http://dx.doi.org/10.3390/cancers16111960.

Full text

Abstract:

Skin cancers involve a significant concern in cancer therapy due to their association with various treatment modalities. This comprehensive review explores the increased risk of skin cancers linked to different anti-cancer treatments, including classic immunosuppressants such as methotrexate (MTX), chemotherapeutic agents such as fludarabine and hydroxyurea (HU), targeted therapies like ibrutinib and Janus Kinase inhibitors (JAKi), mitogen-activated protein kinase pathway (MAPKP) inhibitors, sonic hedgehog pathway (SHHP) inhibitors, and radiotherapy. MTX, a widely used immunosuppressant in dif

APA, Harvard, Vancouver, ISO, and other styles

11

Taritsa, Iulianna, Shikha Walia, and Jennifer Choi. "Demodicosis Mimicking Papulopustular Eruption in the Setting of Targeted Therapy." SKIN The Journal of Cutaneous Medicine 6, no. 1 (2022): 48–51. http://dx.doi.org/10.25251/skin.6.1.9.

Full text

Abstract:

Here we discuss the dramatic cutaneous reactions of two patients receiving targeted therapies for cancer (one on a MEK inhibitor/BRAF inhibitor and the other receiving carfilzomib). Demodicosis was the underlying cause in both cases, though the infection was mistaken for a reaction to the patients’ complex malignancy therapies. Given the prevalence of cutaneous side effects of chemotherapy and targeted cancer therapies and the protean nature of demodicosis, it follows that demodicosis may be easily mistaken as a drug reaction to a chemotherapeutic agent. Demodicosis in the setting of chemother

APA, Harvard, Vancouver, ISO, and other styles

12

Kris, Mark G., Matthew D. Hellmann, and Jamie E. Chaft. "Chemotherapy for Lung Cancers: Here to Stay." American Society of Clinical Oncology Educational Book, no. 34 (May 2014): e375-e380. http://dx.doi.org/10.14694/edbook_am.2014.34.e375.

Full text

Abstract:

Four decades of clinical research document the effectiveness of chemotherapy in patients with lung cancers. Chemotherapeutic agents can improve lung cancer symptoms, lengthen life in most patients with lung cancers, and enhance curability in individuals with locoregional disease when combined with surgery or irradiation. Chemotherapy's effectiveness is enhanced in patients with EGFR-mutant and ALK-positive lung cancers and can “rescue” individuals whose oncogene-driven cancers have become resistant to targeted agents. As immunotherapies become part of the therapeutic armamentarium for lung can

APA, Harvard, Vancouver, ISO, and other styles

13

Essa, Marwa Labib, Maged Abdeltawab El-Kemary, Eman Mohammed Ebrahem Saied, Stefano Leporatti, and Nemany Abdelhamid Nemany Hanafy. "Nano targeted Therapies Made of Lipids and Polymers have Promising Strategy for the Treatment of Lung Cancer." Materials 13, no. 23 (2020): 5397. http://dx.doi.org/10.3390/ma13235397.

Full text

Abstract:

The introduction of nanoparticles made of polymers, protein, and lipids as drug delivery systems has led to significant progress in modern medicine. Since the application of nanoparticles in medicine involves the use of biodegradable, nanosized materials to deliver a certain amount of chemotherapeutic agents into a tumor site, this leads to the accumulation of these nanoencapsulated agents in the right region. This strategy minimizes the stress and toxicity generated by chemotherapeutic agents on healthy cells. Therefore, encapsulating chemotherapeutic agents have less cytotoxicity than non-en

APA, Harvard, Vancouver, ISO, and other styles

14

Narayanan, Sujata, and Sandy Srinivas. "Incorporating VEGF-targeted therapy in advanced urothelial cancer." Therapeutic Advances in Medical Oncology 9, no. 1 (2016): 33–45. http://dx.doi.org/10.1177/1758834016667179.

Full text

Abstract:

Patients with relapsed or refractory urothelial carcinoma (UC) have poor prognosis coupled with few options for systemic treatment. The role of angiogenesis in the evolution of cancers has been established, and studies have shown that it plays a key role in the pathogenesis of UC. Many targeted agents have been used in phase I–II trials for the treatment of UC, with encouraging but modest results. Recently, studies combining angiogenesis inhibitors with other chemotherapeutic agents were able to achieve objective responses higher than most commonly used second-line therapies in UC. Future effo

APA, Harvard, Vancouver, ISO, and other styles

15

Barkat, Harshita Abul, Sabya Sachi Das, Md Abul Barkat, Sarwar Beg, and Hazrina Ab Hadi. "Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress." Future Oncology 16, no. 35 (2020): 2959–79. http://dx.doi.org/10.2217/fon-2020-0198.

Full text

Abstract:

Cancer is one of the leading causes of death worldwide. Regardless of advances in understanding the molecular mechanics of cancer, its treatment is still lacking and the death rates for many forms of the disease remain the same as six decades ago. Although a variety of therapeutic agents and strategies have been reported, these therapies often failed to provide efficient therapy to patients as a consequence of the inability to deliver right and adequate chemotherapeutic agents to the right place. However, the situation has started to revolutionize substantially with the advent of novel ‘target

APA, Harvard, Vancouver, ISO, and other styles

16

Shaham, Salique H., Puneet Vij, and Manish K. Tripathi. "Advances in Targeted and Chemotherapeutic Strategies for Colorectal Cancer: Current Insights and Future Directions." Biomedicines 13, no. 3 (2025): 642. https://doi.org/10.3390/biomedicines13030642.

Full text

Abstract:

Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide, necessitating the continuous evolution of therapeutic approaches. Despite advancements in early detection and localized treatments, metastatic colorectal cancer (mCRC) poses significant challenges due to low survival rates and resistance to conventional therapies. This review highlights the current landscape of CRC treatment, focusing on chemotherapy and targeted therapies. Chemotherapeutic agents, including 5-fluorouracil, irinotecan, and oxaliplatin, have significantly improved survival but face

APA, Harvard, Vancouver, ISO, and other styles

17

Petty, Amy J., and Yiping Yang. "Tumor-Associated Macrophages in Hematologic Malignancies: New Insights and Targeted Therapies." Cells 8, no. 12 (2019): 1526. http://dx.doi.org/10.3390/cells8121526.

Full text

Abstract:

The growth of hematologic malignant cells can be facilitated by other non-tumor cells within the same microenvironment, including stromal, vascular, immune and mesenchymal stem cells. Macrophages are an integral part of the human innate immune system and the tumor microenvironment. Complex interplays between the malignant hematologic cells and the infiltrating macrophages promote the formation of leukemia, lymphoma or myeloma-associated macrophages. These pro-tumorigenic macrophages in turn play an important part in facilitating tumor growth, metastasis and chemotherapeutic resistance. Previou

APA, Harvard, Vancouver, ISO, and other styles

18

Elshazly, Ahmed M., and David A. Gewirtz. "The Cytoprotective Role of Autophagy in Response to BRAF-Targeted Therapies." International Journal of Molecular Sciences 24, no. 19 (2023): 14774. http://dx.doi.org/10.3390/ijms241914774.

Full text

Abstract:

BRAF-targeted therapies are widely used for the treatment of melanoma patients with BRAF V600 mutations. Vemurafenib, dabrafenib as well as encorafenib have demonstrated substantial therapeutic activity; however, as is the case with other chemotherapeutic agents, the frequent development of resistance limits their efficacy. Autophagy is one tumor survival mechanism that could contribute to BRAF inhibitor resistance, and multiple studies support an association between vemurafenib-induced and dabrafenib-induced autophagy and tumor cell survival. Clinical trials have also demonstrated a potential

APA, Harvard, Vancouver, ISO, and other styles

19

Kelly, Ronan J., Iacopo Petrini, Arun Rajan, Yisong Wang, and Giuseppe Giaccone. "Thymic Malignancies: From Clinical Management to Targeted Therapies." Journal of Clinical Oncology 29, no. 36 (2011): 4820–27. http://dx.doi.org/10.1200/jco.2011.36.0487.

Full text

Abstract:

Purpose A key challenge in the treatment of thymoma and thymic carcinoma (TC) is in improving our understanding of the molecular biology of these relatively rare tumors. In recent years, significant efforts have been made to dissect the molecular pathways involved in their carcinogenesis. Here we discuss the results of large-scale genomic analyses conducted to date and review the most active chemotherapies and targeted treatments. Methods We reviewed the literature for chemotherapeutic trials in the last 20 years and trials involving targeted therapies between 1999 and 2010. The search was sup

APA, Harvard, Vancouver, ISO, and other styles

20

Singh, Sunanda, Hector J. Gomez, Shreya Thakkar, Samara P. Singh, and Ashutosh S. Parihar. "Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition." International Journal of Molecular Sciences 24, no. 5 (2023): 4722. http://dx.doi.org/10.3390/ijms24054722.

Full text

Abstract:

Anti-neoplastic agents for cancer treatment utilize many different mechanisms of action and, when combined, can result in potent inhibition of cancer growth. Combination therapies can result in long-term, durable remission or even cure; however, too many times, these anti-neoplastic agents lose their efficacy due to the development of acquired drug resistance (ADR). In this review, we evaluate the scientific and medical literature that elucidate STAT3-mediated mechanisms of resistance to cancer therapeutics. Herein, we have found that at least 24 different anti-neoplastic agents—standard toxic

APA, Harvard, Vancouver, ISO, and other styles

21

Nadora, Denise, Shawyon Ezzati, Brandon Bol, and Orwa Aboud. "Serendipity in Neuro-Oncology: The Evolution of Chemotherapeutic Agents." International Journal of Molecular Sciences 26, no. 7 (2025): 2955. https://doi.org/10.3390/ijms26072955.

Full text

Abstract:

The development of novel therapeutics in neuro-oncology faces significant challenges, often marked by high costs and low success rates. Despite advances in molecular biology and genomics, targeted therapies have had limited impact on improving patient outcomes in brain tumors, particularly gliomas, due to the complex, multigenic nature of these malignancies. While significant efforts have been made to design drugs that target specific signaling pathways and genetic mutations, the clinical success of these rational approaches remains sparse. This review critically examines the landscape of neur

APA, Harvard, Vancouver, ISO, and other styles

22

Shi, Xutao. "Lung cancer drug development: From traditional chemotherapy to targeted and immunotherapies." Theoretical and Natural Science 58, no. 1 (2024): 1–8. http://dx.doi.org/10.54254/2753-8818/58/20241317.

Full text

Abstract:

Abstract. Lung cancer remains one of the deadliest types of cancer in the world, with the number of deaths due to lung cancer increasing dramatically year after year. In the same period, the approach to the treatment of lung cancer has changed dramatically over the past few decades, from systemic chemotherapeutic drugs-platinum-based drugs in the beginning to a wide range of newer therapeutic approaches such as targeted therapies and immunotherapies at the present time. This article reviews the development of drug therapy for lung cancer. By comparing the differences in mechanism of action and

APA, Harvard, Vancouver, ISO, and other styles

23

Bhatia, Sugandha, Tony Blick, Cletus Pinto, et al. "Identifying Therapies to Combat Epithelial Mesenchymal Plasticity-Associated Chemoresistance to Conventional Breast Cancer Therapies Using An shRNA Library Screen." Cancers 12, no. 5 (2020): 1123. http://dx.doi.org/10.3390/cancers12051123.

Full text

Abstract:

Background: Breast cancer (BC) is a heterogeneous disease for which the commonly used chemotherapeutic agents primarily include the anthracyclines (doxorubicin, epirubicin), microtubule inhibitors (paclitaxel, docetaxel, eribulin), and alkylating agents (cyclophosphamide). While these drugs can be highly effective, metastatic tumours are frequently refractory to treatment or become resistant upon tumour relapse. Methods: We undertook a cell polarity/epithelial mesenchymal plasticity (EMP)-enriched short hairpin RNA (shRNA) screen in MDA-MB-468 breast cancer cells to identify factors underpinni

APA, Harvard, Vancouver, ISO, and other styles

24

Yun, Jang-Hyuk, Yoo Rim Noh, Seongkyeong Yoo, et al. "Harnessing Extracellular Vesicles for Targeted Drug Delivery in Ovarian Cancer." Pharmaceutics 17, no. 4 (2025): 528. https://doi.org/10.3390/pharmaceutics17040528.

Full text

Abstract:

Ovarian cancer remains one of the most lethal gynecologic malignancies, primarily due to late-stage diagnosis, high recurrence rates, and the development of chemoresistance. Although targeted therapies have improved patient outcomes, their efficacy is often limited by off-target toxicity and acquired drug resistance. Extracellular vesicles (EVs), nanoscale vesicles naturally released by cells, have emerged as promising carriers for precision drug delivery. This review provides a comprehensive overview of recent advances in EV-based therapeutic strategies for ovarian cancer, including the deliv

APA, Harvard, Vancouver, ISO, and other styles

25

Halama, Niels, Inka Zoernig, and Dirk Jaeger. "Advanced Malignant Melanoma: Immunologic and Multimodal Therapeutic Strategies." Journal of Oncology 2010 (2010): 1–8. http://dx.doi.org/10.1155/2010/689893.

Full text

Abstract:

Immunologic treatment strategies are established in malignant melanoma treatment, mainly focusing on Interleukin-2 in advanced disease and interferon alpha in the adjuvant situation. In advanced disease, therapies with IL-2, interferon and different chemotherapeutic agents were not associated with better patient survival in the vast majority of patients. Therefore, an overview of novel immunological agents and combined therapeutic approaches is presented in this review, covering allogenic and autologous vaccine strategies, dendritic cell vaccination, strategies for adoptive immunotherapy and T

APA, Harvard, Vancouver, ISO, and other styles

26

Samanta, Kamalika, Saini Setua, Sonam Kumari, Meena Jaggi, Murali M. Yallapu, and Subhash C. Chauhan. "Gemcitabine Combination Nano Therapies for Pancreatic Cancer." Pharmaceutics 11, no. 11 (2019): 574. http://dx.doi.org/10.3390/pharmaceutics11110574.

Full text

Abstract:

Pancreatic cancer is one of the deadliest causes of cancer-related death in the United States, with a 5-year overall survival rate of 6 to 8%. These statistics suggest that immediate medical attention is needed. Gemcitabine (GEM) is the gold standard first-line single chemotherapy agent for pancreatic cancer but, after a few months, cells develop chemoresistance. Multiple clinical and experimental investigations have demonstrated that a combination or co-administration of other drugs as chemotherapies with GEM lead to superior therapeutic benefits. However, such combination therapies often ind

APA, Harvard, Vancouver, ISO, and other styles

27

Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, Beth, and Tiffany Richards, PhD, ANP-BC, AOCNP. "Introduction." Journal of the Advanced Practitioner in Oncology 13, no. 5 (2022): 6. http://dx.doi.org/10.6004/jadpro.2022.13.5.9.

Full text

Abstract:

Advances in the diagnosis and management of multiple myeloma (MM) and other plasma cell disorders such as AL amyloidosis and Waldenström macroglobulinemia (WM) continue to evolve rapidly. Over the past several years, there have been significant gains in understanding disease biology, leading to improvements in diagnostic techniques, a shift towards targeted therapies, and a potential transition away from traditional chemotherapeutic agents as the standard of care.

APA, Harvard, Vancouver, ISO, and other styles

28

Parent, Ephraim E., and Adam M. Kase. "A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer." Cancers 14, no. 17 (2022): 4276. http://dx.doi.org/10.3390/cancers14174276.

Full text

Abstract:

The recent approval of 177Lu PSMA-617 (Pluvicto®) by the United States Food and Drug Administration (FDA) is the culmination of decades of work in advancing the field of targeted radionuclide therapy for metastatic prostate cancer. 177Lu PSMA-617, along with the bone specific radiotherapeutic agent, 223RaCl2 (Xofigo®), are now commonly used in routine clinical care as a tertiary line of therapy for men with metastatic castrate resistant prostate cancer and for osseus metastatic disease respectively. While these radiopharmaceuticals are changing how metastatic prostate cancer is classified and

APA, Harvard, Vancouver, ISO, and other styles

29

Murphy, Lindsey A., and Amanda C. Winters. "Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells." Biomedicines 11, no. 12 (2023): 3248. http://dx.doi.org/10.3390/biomedicines11123248.

Full text

Abstract:

Acute myeloid leukemia (AML) is a rare subtype of acute leukemia in the pediatric and adolescent population but causes disproportionate morbidity and mortality in this age group. Standard chemotherapeutic regimens for AML have changed very little in the past 3–4 decades, but the addition of targeted agents in recent years has led to improved survival in select subsets of patients as well as a better biological understanding of the disease. Currently, one key paradigm of bench-to-bedside practice in the context of adult AML is the focus on leukemia stem cell (LSC)-targeted therapies. Here, we r

APA, Harvard, Vancouver, ISO, and other styles

30

De Giorgi, Ugo, Chiara Casadei, Alice Bergamini, et al. "Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors." Cancers 11, no. 10 (2019): 1584. http://dx.doi.org/10.3390/cancers11101584.

Full text

Abstract:

The majority of patients with advanced ovarian germ cell cancer are treated by cisplatin-based chemotherapy. Despite adequate first-line treatment, nearly one third of patients relapse and almost half develop cisplatin-resistant disease, which is often fatal. The treatment of cisplatin-resistant disease is challenging and prognosis remains poor. There are limited data on the efficacy of specific chemotherapeutic regimens, high-dose chemotherapy with autologous progenitor cell support and targeted therapies. The inclusion of patients in clinical trials is strongly recommended, especially in cli

APA, Harvard, Vancouver, ISO, and other styles

31

Harrell, Carl Randall, Ana Volarevic, Valentin Djonov, and Vladislav Volarevic. "Mesenchymal Stem-Cell-Derived Exosomes as Novel Drug Carriers in Anti-Cancer Treatment: A Myth or Reality?" Cells 14, no. 3 (2025): 202. https://doi.org/10.3390/cells14030202.

Full text

Abstract:

Although cancer therapy has significantly advanced in recent decades, patients and healthcare professionals are still quite concerned about adverse effects due to the non-targeted nature of currently used chemotherapeutics. Results obtained in a large number of recently published experimental studies indicated that mesenchymal stem-cell-derived exosomes (MSC-Exos), due to their biocompatibility, ability to cross biological barriers, and inherent targeting capabilities, could be used as a promising drug-delivery system for anti-cancer therapies. Their lipid bilayer protects cargo of anti-cancer

APA, Harvard, Vancouver, ISO, and other styles

32

Yang, Enguang, Suoshi Jing, Yuhan Wang, Hanzhang Wang, Ronald Rodriguez, and Zhiping Wang. "The Role of Mesenchymal Stem Cells and Exosomes in Tumor Development and Targeted Antitumor Therapies." Stem Cells International 2023 (February 14, 2023): 1–15. http://dx.doi.org/10.1155/2023/7059289.

Full text

Abstract:

Mesenchymal stem cells (MSCs) can be isolated from various tissues in adults and differentiated into cells of the osteoblasts, adipocytes, chondrocytes, and myocytes. Recruitments of MSCs towards tumors have a crucial contribution to tumor development. However, the role of MSCs in the tumor microenvironment is uncertain. In addition, due to its tropism to the tumor and low immunogenic properties, more and more pieces of evidence indicate that MSCs may be an ideal carrier for antitumor biologics such as cytokines, chemotherapeutic agents, and oncolytic viruses. Here, we review the existing know

APA, Harvard, Vancouver, ISO, and other styles

33

Gurnari, Carmelo, Simona Pagliuca, and Valeria Visconte. "Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia." International Journal of Molecular Sciences 21, no. 22 (2020): 8505. http://dx.doi.org/10.3390/ijms21228505.

Full text

Abstract:

Acute myeloid leukemia (AML) is a clonal hematopoietic disorder characterized by abnormal proliferation, lack of cellular differentiation, and infiltration of bone marrow, peripheral blood, or other organs. Induction failure and in general resistance to chemotherapeutic agents represent a hindrance for improving survival outcomes in AML. Here, we review the latest insights in AML biology concerning refractoriness to therapies with a specific focus on cytarabine and daunorubicin which still represent milestones agents for inducing therapeutic response and disease eradication. However, failure t

APA, Harvard, Vancouver, ISO, and other styles

34

Aubin, Francine, and Charles D. Blanke. "Pre-operative Targeted Therapies in Patients with Hepatic Colorectal Cancer Metastases—Bevacizumab versus Cetuximab." Oncology & Hematology Review (US) 06 (2010): 42. http://dx.doi.org/10.17925/ohr.2010.06.0.42.

Full text

Abstract:

Complete resection offers the greatest chance of cure for patients with isolated colorectal cancer liver metastases. While few patients present as candidates for curative surgery, induction chemotherapy may make patients with initially unresectable disease amenable to surgery. Even those whose disease is potentially curable at presentation may benefit from pre-operative neoadjuvant systemic therapy, particularly those deemed at high risk for relapse. Biological targeted therapies such as bevacizumab and cetuximab improve on standard systemic chemotherapeutic regimens in incurable patients; the

APA, Harvard, Vancouver, ISO, and other styles

35

Fukushima, Toshirou, Daisuke Gomi, Noriko Seno, et al. "Successful Salvage Chemotherapy with Streptozocin in a Patient with Mediastinal Atypical Carcinoid Tumor Who Had Relapsed after Various Prior Therapies." Case Reports in Oncology 11, no. 1 (2018): 49–54. http://dx.doi.org/10.1159/000477163.

Full text

Abstract:

Pulmonary neuroendocrine tumors are rare, and there have been very few reports regarding optimal chemotherapeutic regimens. Two molecular targeted agents, everolimus and sunitinib, have recently been shown to provide an additional treatment benefit for pulmonary neuroendocrine tumors. However, little information is available regarding the usefulness of streptozocin chemotherapy. Here, we encountered a case of relapsed and refractory mediastinal atypical carcinoid tumor associated with multiple endocrine neoplasia type 1 for various cytotoxic and molecular targeted agents. The patient showed a

APA, Harvard, Vancouver, ISO, and other styles

36

Oliver, Kate E., and John H. Farley. "Cisplatin plus Cetuximab in the Treatment of Recurrent and Persistent Cancers of the Cervix." Oncology & Hematology Review (US) 06 (2010): 45. http://dx.doi.org/10.17925/ohr.2010.06.0.45.

Full text

Abstract:

With the discovery of the human genome, new frontiers in the treatment of cancer include the development of targeted biologic therapies directed at tumor-specific antigens. Novel targeted molecular therapies provide more specific antitumor activity than traditional chemotherapeutic agents while simultaneously improving toxicity. Cetuximab is a recombinant monoclonal antibody directed at the epidermal growth factor receptor (EGFR). EGFR serves as the gatekeeper to the intracellular pathways responsible for angiogenesis, metastasis, cellular growth, and survival. EGFR overexpression has been dem

APA, Harvard, Vancouver, ISO, and other styles

37

Stull, Dawn Marie. "Current Trends in the Treatment of Acute and Chronic Myelogenous Leukemia." Journal of Pharmacy Practice 15, no. 1 (2002): 62–74. http://dx.doi.org/10.1106/ujqk-83t8-kacc-0auy.

Full text

Abstract:

Acute myelogenous and chronic myelogenous leukemia are uniformly fatal if left untreated. Treatment with conventional chemotherapeutic agents results in a cure for a small percentage of patients and substantial toxicities in all patients that receive treatment. The first of a new generation of “targeted therapies” has recently been introduced. It is hoped that these agents will demonstrate enhanced efficacy and a decreased toxicity profile. Gemtuzumab ozogamicin (Mylotarg™) is the first antibody-targeted therapy approved for use in patients with acute myelogeneous leukemia, arsenic trioxide (T

APA, Harvard, Vancouver, ISO, and other styles

38

Witkowska, Marta, Ewelina Golusińska-Kardach, Wojciech Golusiński, and Ewa Florek. "Polydopamine-Based Material and Their Potential in Head and Neck Cancer Therapy—Current State of Knowledge." International Journal of Molecular Sciences 24, no. 5 (2023): 4890. http://dx.doi.org/10.3390/ijms24054890.

Full text

Abstract:

Head and neck cancers (HNC) are among the most common cancers in the world. In terms of frequency of occurrence in the world, HNC ranks sixth. However, the problem of modern oncology is the low specificity of the therapies used, which is why most of the currently used chemotherapeutic agents have a systemic effect. The use of nanomaterials could overcome the limitations of traditional therapies. Researchers are increasingly using polydopamine (PDA) in nanotherapeutic systems for HNC due to its unique properties. PDA has found applications in chemotherapy, photothermal therapy, targeted therapy

APA, Harvard, Vancouver, ISO, and other styles

39

Saly, Danielle L., and Mark A. Perazella. "The adverse kidney effects of cancer immunotherapies." Journal of Onco-Nephrology 2, no. 2-3 (2018): 56–68. http://dx.doi.org/10.1177/2399369318808806.

Full text

Abstract:

Cancer therapies are a common cause of acute and chronic kidney disease, which are increasingly being seen by nephrologists in clinical practice. Conventional chemotherapeutic drugs and novel targeted agents are effective cancer therapies but their use is complicated by nephrotoxicity. Cancer immunotherapies exploit various properties of immune cells to enhance immune-mediated tumor killing. Interferon and high-dose interleukin-2 are older immunotherapies first employed clinically in the 1980s and 1990s to treat a number of different cancers. While effective, these two therapies have well-know

APA, Harvard, Vancouver, ISO, and other styles

40

Ojima, Iwao. "Tumor-targeting drug delivery of chemotherapeutic agents." Pure and Applied Chemistry 83, no. 9 (2011): 1685–98. http://dx.doi.org/10.1351/pac-con-11-02-10.

Full text

Abstract:

Despite the significant progress in the development of cancer detection, prevention, surgery, and therapy, there is still no common cure for this disease. In addition, the long-standing problem of chemotherapy is the lack of tumor-specific treatments. Traditional chemotherapy relies on the premise that rapidly proliferating cancer cells are more likely to be killed by a cytotoxic agent. In reality, however, cytotoxic agents have very little or no specificity, which leads to systemic toxicity, causing undesirable severe side effects. Therefore, various “molecularly targeted cancer therapies” ha

APA, Harvard, Vancouver, ISO, and other styles

41

Mayur, Narkhede1* Pooja Shinde2. "Recent Advances in Amino-Functionalized Mesoporous Silica Nanoparticles for Targeted Breast Cancer Therapy." International Journal of Pharmaceutical Sciences 3, no. 3 (2025): 3068–95. https://doi.org/10.5281/zenodo.15108463.

Full text

Abstract:

Breast cancer, which represents a leading cause of cancer-related deaths around the world, poses challenges such as therapeutic resistance, poor specificity of treatments, and systemic toxicity. Amino-functionalized mesoporous silica nanoparticles (MSNs) represent innovative platforms for targeted therapy of breast cancer. With extremely high surface area, tuneable pore size, and versatile functionalization potential, MSNs are shown to efficiently encapsulate chemotherapeutics, genetic materials, and imaging agents. This functionalisation increases drug loading capabilities, stability, and sti

APA, Harvard, Vancouver, ISO, and other styles

42

Alshehri, Ali H. D. "Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies." Diagnostics 14, no. 21 (2024): 2407. http://dx.doi.org/10.3390/diagnostics14212407.

Full text

Abstract:

Recent advances have broadened the range of therapeutic options for mCRPC, with several new treatments, including novel hormonal therapies (enzalutamide, abiraterone), chemotherapeutic agents (docetaxel, cabazitaxel), immunotherapies (sipuleucel-T), and bone targeting radiopharmaceuticals (radium-223) showing improved clinical outcomes and receiving U.S. Food and Drug Administration approval. These new treatments provide new avenues for improving patient survival and quality of life. Radium-223, a targeted alpha-emitter, specifically targets bone metastases, offering palliative benefits and a

APA, Harvard, Vancouver, ISO, and other styles

43

Rosales, Joseph, and Lucille A. Leong. "Chemotherapy for Metastatic Colorectal Cancer." Journal of the National Comprehensive Cancer Network 3, no. 4 (2005): 525–29. http://dx.doi.org/10.6004/jnccn.2005.0028.

Full text

Abstract:

The past decade has seen a significant survival improvement for patients with metastatic colorectal cancer, fueled in large part by the arrival of active novel chemotherapeutic drugs and their incorporation into combination regimens. Several randomized trials have successfully integrated oxaliplatin and irinotecan into previously existing 5-fluorouracil (5-FU)-based regimens for advanced colorectal cancer, resulting in median survivals that have risen from 9 months to almost 2 years. Even as the ideal combinations and sequences of these regimens are elucidated, targeted therapies such as recen

APA, Harvard, Vancouver, ISO, and other styles

44

Abdulmalek, Shaymaa, Nouf Mostafa, Marwa Gomaa, Mohamed El‑Kersh, Ayman I. Elkady, and Mahmoud Balbaa. "Bee venom-loaded EGFR-targeting peptide-coupled chitosan nanoparticles for effective therapy of hepatocellular carcinoma by inhibiting EGFR-mediated MEK/ERK pathway." PLOS ONE 17, no. 8 (2022): e0272776. http://dx.doi.org/10.1371/journal.pone.0272776.

Full text

Abstract:

Hepatocellular carcinoma (HCC) is one of the world’s most risky diseases due to the lack of clear and cost-effective therapeutic targets. Currently, the toxicity of conventional chemotherapeutic medications and the development of multidrug resistance is driving research into targeted therapies. The nano-biomedical field’s potential for developing an effective therapeutic nano-sized drug delivery system is viewed as a significant pharmaceutical trend for the encapsulation and release of numerous anticancer therapies. In this regard, current research is centered on the creation of biodegradable

APA, Harvard, Vancouver, ISO, and other styles

45

Watson, Jim. "Oxidants, antioxidants and the current incurability of metastatic cancers." Open Biology 3, no. 1 (2013): 120144. http://dx.doi.org/10.1098/rsob.120144.

Full text

Abstract:

The vast majority of all agents used to directly kill cancer cells (ionizing radiation, most chemotherapeutic agents and some targeted therapies) work through either directly or indirectly generating reactive oxygen species that block key steps in the cell cycle. As mesenchymal cancers evolve from their epithelial cell progenitors, they almost inevitably possess much-heightened amounts of antioxidants that effectively block otherwise highly effective oxidant therapies. Also key to better understanding is why and how the anti-diabetic drug metformin (the world's most prescribed pharmaceutical p

APA, Harvard, Vancouver, ISO, and other styles

46

Ahmed, Mohammed Abduljabbar. "Design and Synthesis of Biodegradable Polymeric Nanoparticles for Targeted Delivery of Chemotherapeutics in Triple-Negative Breast Cancer." SHIFAA 2023 (April 21, 2023): 1–11. http://dx.doi.org/10.70470/shifaa/2023/004.

Full text

Abstract:

Type three breast cancer (TNBC) is a highly aggressive form of breast cancer that lacks targeted therapies, leading to poor prognosis and limited therapeutic options The development of biodegradable polymeric nanoparticles (NPs) provides find a promising strategy for targeted delivery of chemotherapeutic drugs to reduce systemic toxicity , enhancing therapeutic efficacy This review focuses on the design and synthesis of biodegradable polymeric nanoparticles for targeted delivery of chemotherapeutic agents in TNBC. Polymeric nanoparticles were synthesized from biocompatible and biodegradable ma

APA, Harvard, Vancouver, ISO, and other styles

47

Yuan, Hui, Miao Bao, Minqiang Chen, Junhao Fu, and Shian Yu. "Advances in Immunotherapy and Targeted Therapy for Gastric Cancer: A Comprehensive Review." British Journal of Hospital Medicine 86, no. 3 (2025): 1–24. https://doi.org/10.12968/hmed.2024.0759.

Full text

Abstract:

Gastric cancer remains one of the most prevalent and lethal malignancies worldwide, characterized by poor survival rates, particularly in advanced stages. In recent years, a paradigm shift in gastric cancer treatment has been witnessed with the introduction of immunotherapy and targeted therapies. This review provides a detailed examination of current immunotherapeutic strategies, including adoptive cell therapy (ACT), immune checkpoint inhibitors (ICIs), and cancer vaccines. Additionally, it explores advancements in targeted therapies, focusing on the human epidermal growth factor receptor 2

APA, Harvard, Vancouver, ISO, and other styles

48

Badrinath, Narayanasamy, and So Yoo. "Recent Advances in Cancer Stem Cell-Targeted Immunotherapy." Cancers 11, no. 3 (2019): 310. http://dx.doi.org/10.3390/cancers11030310.

Full text

Abstract:

Cancer stem cells (CSCs) are one of the reasons for the relapse of cancer cells and metastasis. They have drug resistance against most chemotherapeutic agents. CSCs are also responsible for tumor cell heterogeneity and cause minimal residual disease. In order to achieve complete regression of tumors, CSCs have to be targeted. Recent advances in immunotherapies have shown promising outcomes in curing cancer, which are also applicable to target CSCs. CSCs express immune markers and exhibit specific immune characteristics in various cancers, which can be used in immunotherapies to target CSCs in

APA, Harvard, Vancouver, ISO, and other styles

49

Rudnicka, Katarzyna, Paulina Lemieszek, Katarzyna Krukar, et al. "Targeted Cancer Therapy: The Role of Liposomes in Oncology. A Literature Review." Journal of Education, Health and Sport 69 (October 2, 2024): 55349. http://dx.doi.org/10.12775/jehs.2024.69.55349.

Full text

Abstract:

Liposomal formulations represent a significant advancement in the field of oncology, providing innovative solutions for the delivery of chemotherapeutic agents. These nanoscale carriers, made of phospholipid bilayers, enhance drug stability and allow for targeted delivery to tumor tissues, thereby improving the therapeutic index of anticancer medications. By altering the pharmacokinetics and biodistribution of these drugs, liposomes help reduce systemic side effects while increasing the concentration of therapeutic agents at the tumor site. Recent developments in liposomal technology have led

APA, Harvard, Vancouver, ISO, and other styles

50

Shah, Kanisha, and Rakesh M. Rawal. "Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities." Current Drug Metabolism 20, no. 14 (2020): 1114–31. http://dx.doi.org/10.2174/1389200221666200103111539.

Full text

Abstract:

Cancer is a complex disease that has the ability to develop resistance to traditional therapies. The current chemotherapeutic treatment has become increasingly sophisticated, yet it is not 100% effective against disseminated tumours. Anticancer drugs resistance is an intricate process that ascends from modifications in the drug targets suggesting the need for better targeted therapies in the therapeutic arsenal. Advances in the modern techniques such as DNA microarray, proteomics along with the development of newer targeted drug therapies might provide better strategies to overcome drug resist

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!